cladribine has been researched along with Hematologic Malignancies in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Kong, P; Yao, H | 1 |
| Bigenzahn, JW; Choi, HS; Felberbauer, F; Gisslinger, H; Gültekin, S; Hoermann, G; Jäger, U; Jeryczynski, G; Kazianka, L; Kenner, L; Korkmaz, B; Kornauth, C; Krall, N; Kralovics, R; Kubicek, S; Lopez de la Fuente, O; Mayerhoefer, ME; Merkel, O; Miura, K; Müllauer, L; Ocko, K; Prager, GW; Prutsch, N; Ringler, A; Sabler, M; Schmolke, AS; Simonitsch-Klupp, I; Snijder, B; Sperr, WR; Staber, PB; Superti-Furga, G; Valent, P; van der Kouwe, E; Vladimer, GI | 1 |
| Anwar, A; Becker, PS; Buckley, SA; Cassaday, RD; Chen, TL; Estey, EH; Gardner, KM; Halpern, AB; Hendrie, PC; Huebner, EM; Oehler, VG; Orlowski, KF; Orozco, JJ; Othus, M; Percival, MM; Scott, BL; Smith, HA; Walter, RB | 1 |
| Pardanani, A | 1 |
| Barshack, I; Feldberg, E; Filanovsky, K; Shvidel, L; Ustaev, E; Vorst, E; Yacobi, R | 1 |
| Miller, HJ; Saven, A; Schram, ED; Sigal, DS | 1 |
| Allred, JB; Ansell, SM; Dispenzieri, A; Elliott, MA; Gastineau, DA; Gertz, MA; Geyer, SM; Hogan, WJ; Inwards, DJ; Lacy, MQ; Larsen, JT; Litzow, MR; Micallef, IN; Porrata, LF; Roy, V; Tefferi, A; Tun, HW; Wu, W | 1 |
| Chow, KU; Hoelzer, D; Kim, SZ; Kriener, S; Mitrou, PS; Schui, DK; Sterry, W; Weidmann, E; Zollner, TM | 1 |
| Kami, M; Kanda, Y; Makimoto, A; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
| Albertioni, F; Juliusson, G; Lotfi, K | 1 |
| Daugherty, CK; Huo, D; Janisch, L; Larson, RA; Odenike, OM; Ratain, MJ; Sobecks, RM; Zimmerman, TM | 1 |
| Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ | 1 |
| Korycka, A; Robak, E; Robak, T | 1 |
| Robak, E; Robak, T; Wierzbowska, A | 1 |
| Hamaki, T; Hori, A; Kami, M; Kanda, Y; Katayama, Y; Kishi, Y; Kobayashi, K; Mori, S; Murashige, N; Onishi, Y; Tajima, K; Takaue, Y; Tanosaki, R | 1 |
| Gandhi, V; Plunkett, W | 1 |
| Anderlini, P; Andersson, BS; Andreeff, M; Braunschweig, I; Bruton, J; Champlin, R; Claxton, D; Cohen, A; Davis, M; Donato, M; Gajewski, J; Giralt, S; Ippolitti, C; Khouri, I; Kornblau, S; Molldrem, J; Przepiorka, D; Thall, PF; Ueno, NT; Wang, X | 1 |
| Johnson, SA | 1 |
| Boehrer, S; Bojunga, J; Chow, KU; Fauth, F; Hoelzer, D; Martin, H; Mitrou, PS; Rummel, MJ; Schneider, B; Stieler, M; Weidmann, E | 1 |
8 review(s) available for cladribine and Hematologic Malignancies
| Article | Year |
|---|---|
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Cladribine; Disease Management; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Interleukin-2 Receptor alpha Subunit; Mast Cells; Mastocytosis, Systemic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Assessment; Staurosporine; Survival Analysis; Transplantation, Homologous; Tryptases | 2019 |
Beyond hairy cell: the activity of cladribine in other hematologic malignancies.
Topics: Antineoplastic Agents; Cladribine; Hematologic Neoplasms; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia | 2010 |
CD4+ CD56+ neoplasia: clinical and biological features with emphasis on cytotoxic drug-induced apoptosis and expression of sialyl Lewis X.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; CD4 Antigens; CD56 Antigen; Cladribine; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Hematologic Neoplasms; Humans; Immunophenotyping; Lewis X Antigen; Oligosaccharides; Sialyl Lewis X Antigen | 2003 |
Pharmacological basis for cladribine resistance.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; Antineoplastic Agents; Biological Transport; Cladribine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Ribonucleotide Reductases | 2003 |
Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Cladribine; Drug Interactions; Hematologic Neoplasms; Humans; Patents as Topic | 2006 |
Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders.
Topics: Antineoplastic Agents; Autoimmune Diseases; Cladribine; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple Sclerosis; Treatment Outcome | 2006 |
Pharmacology of purine nucleoside analogues.
Topics: Animals; Antineoplastic Agents; Cladribine; Hematologic Neoplasms; Humans; Pentostatin; Purine Nucleosides; Vidarabine | 1996 |
Nucleoside analogues in the treatment of haematological malignancies.
Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Cladribine; Clinical Trials as Topic; Cytarabine; Cytosine; Deoxycytidine; Dioxolanes; Economics, Pharmaceutical; Gemcitabine; Guidelines as Topic; Hematologic Neoplasms; Humans; Molecular Structure; Nucleosides; Pentostatin; Vidarabine | 2001 |
6 trial(s) available for cladribine and Hematologic Malignancies
| Article | Year |
|---|---|
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; Disease-Free Survival; Female; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Microscopy, Fluorescence; Middle Aged; Odds Ratio; Pilot Projects; Piperidines; Positron Emission Tomography Computed Tomography; Pyrazoles; Pyrimidines; Remission Induction; ROC Curve; Young Adult | 2017 |
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Rate | 2019 |
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2013 |
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Administration Schedule; Fatigue; Feasibility Studies; Female; Gemcitabine; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Thrombocytopenia | 2004 |
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladribine; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Topics: Acute Disease; Adenosine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
5 other study(ies) available for cladribine and Hematologic Malignancies
| Article | Year |
|---|---|
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cladribine; Cytarabine; Dendritic Cells; Doxorubicin; Hematologic Neoplasms; Humans; Male; Prognosis; Remission Induction; Salvage Therapy | 2020 |
Second hematologic malignancies in hairy cell leukemia: report of two patients with dynamic mutations in the BRAF gene.
Topics: Antigens, CD20; Antineoplastic Agents; Cladribine; DNA Mutational Analysis; Female; Hematologic Neoplasms; Humans; Immunohistochemistry; Leukemia, Hairy Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Neoplasms, Second Primary; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins B-raf | 2015 |
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Middle Aged; Proportional Hazards Models; Recurrence; Stem Cell Transplantation; Survival Rate; Thyroglobulin; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Disease-Free Survival; Family; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Retrospective Studies; Time Factors; Transplantation, Homologous; Vidarabine | 2008 |
Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Cladribine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Mitoxantrone | 2002 |